The US just picked a fight with its closest European ally over pill prices. On June 18, the US Trade Representative launched a formal Section 301 investigation into Germany’s pharmaceutical pricing practices, alleging that Berlin’s reimbursement policies amount to “persistent underpayment for innovative pharmaceutical products.”

The core argument from Washington: German price controls force American patients and companies to effectively subsidize global drug research and development costs.

What Section 301 actually means

Section 301 gives the USTR authority to investigate foreign trade practices deemed unreasonable, unjustifiable, or discriminatory, and then impose tariffs or other restrictions if the investigation finds merit. It’s the same tool the US famously used against China in 2018 to justify sweeping tariffs on hundreds of billions of dollars in goods.

In this case, USTR Jamieson Greer is turning that tool toward Berlin. The investigation will assess whether Germany’s drug pricing policies are unreasonable or discriminatory and whether they burden US commerce.

A public comments docket opens on June 25, giving industry stakeholders their chance to weigh in. A formal public hearing is scheduled for September 22.

This probe didn’t materialize out of thin air. It follows months of bilateral discussions between US and German officials that, by all indications, went nowhere productive.

The political backdrop

Just two days before the USTR’s announcement, on June 16, a group of 23 Senate Republicans sent a letter urging action against foreign drug pricing practices.

Meanwhile, Germany is reportedly fast-tracking legislation designed to further reduce federal spending on innovative medicines.

The investigation is also part of a broader wave of 2026 Section 301 actions targeting multiple countries, suggesting the pharmaceutical pricing complaint against Germany isn’t an isolated grudge match.

What this means for investors

If the USTR ultimately finds that Germany’s pricing practices harm US commerce, retaliatory tariffs on German pharmaceutical exports are on the table, as are other trade measures that could restrict market access for certain drugs flowing in either direction.

For large-cap US pharmaceutical companies, a favorable ruling might eventually force higher drug prices in Germany and potentially across the EU. Escalating trade tensions could also invite retaliatory measures from the European Union. German pharmaceutical giants face direct risk to their US market access, which for many European pharma companies represents their single largest revenue source.

If the US successfully uses Section 301 to challenge pharmaceutical pricing policies in Germany, it establishes a template for similar actions against the UK, France, Japan, Canada, and dozens of others. The September 22 public hearing will be the next major milestone to watch.